CytomX reports updated Phase I data for CX-072 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) reported updated data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as monotherapy and in combination with anti-CTLA-4 mAb Yervoy ipilimumab or BRAF

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE